Multicenter Study Comparing AI-Based Navicam vs. Conventional Pillcam in Small Bowel Pathology (NAVIPILL)

Hospital Clinic of Barcelona

Status: Enrolling

Conditions: Small Intestine Disease

Treatments: Device: Navicam SB capsule; Device: Pillcam SB3

Study type: Interventional

Funder types: Other

Identifiers

NCT06462352

NAVIPILL

Details and patient eligibility

About

Since its introduction in 2001, small bowel capsule endoscopy has been pivotal in diagnosing small bowel pathology due to its minimally invasive nature and high diagnostic accuracy. However, the technology has limitations, including prolonged reading times and the need for specialized endoscopists. The Navicam endoscopic capsule, leveraging artificial intelligence (AI) with ProScan™ for automated reading, promises to address these limitations by reducing reading times and enhancing diagnostic efficiency.

This study aims to assess the diagnostic concordance and to compare the efficiency of the AI-based Navicam capsule with the conventional Pillcam SB3 in the exploration of the small bowel.

Full description

This is a prospective, multicenter, randomized, observational study involving multiple hospitals across Spain. At each site, patients will ingest both the Pillcam SB3 and Navicam capsules in a randomized order. Reading times, transit times, and diagnostic yield will be compared between the two devices. A central reading committee of experienced gastroenterologists will conduct blinded evaluations of both explorations using predefined criteria.

The primary endpoint is the diagnostic concordance between Navicam's AI-driven ProScan™ system and the conventional reading of Pillcam SB3, measured by Cohen's kappa index.

The secondary endpoints include to assess the correlation in lesion detection, video download times, gastric and small bowel transit times, total reading times, and adverse events.

The sample size is 147 patients, accounting for an expected 10% dropout rate, based on previous studies showing a diagnostic concordance kappa index of 0.6.

This study aims to establish that the AI-based Navicam capsule is at least as effective as the conventional Pillcam SB3 in diagnosing small bowel lesions, with potentially reduced reading times, thus enhancing clinical efficiency in small bowel diagnostics.

Enrollment: 147 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Outpatients over 18 years of age with any clinical indication to undergo a small bowel exploration using capsule endoscopy at the participating hospital.

Exclusion criteria

• Patients with known small bowel strictures detected by computed tomography (CT) or magnetic resonance imaging (MRI).
• Patients with a history of esophagogastric and small bowel surgery (excluding ileocecal resection).
• Patients with a clinical contraindication for small bowel capsule endoscopy.
• Hospitalized patients.
• Patients with pacemaker or Implantable Cardioverter Defibrillator (ICD).
• Patients scheduled for a MRI within 15 days after capsule endoscopy ingestion.
• Pregnant or actively breastfeeding patients.
• Patients with swallowing disorders requiring endoscopic placement of the capsule.
• Simultaneous participation in another clinical trial using any investigational drug or device.
• Concurrent life-threatening pathology or condition.
• Inability to sign the informed consent form.

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

147 participants in 2 patient groups

Navicam endoscopic capsule

Experimental group

Description:

Navicam endoscopic capsule device for the study of small bowel pathology.

Treatment:

Device: Navicam SB capsule

Pillcam endoscopic capsule

Active Comparator group

Description:

Pillcam SB3 endoscopic capsule device for the study of small bowel pathology.

Treatment:

Device: Pillcam SB3